NX Prenatal Invested 2016

NX Prenatal is a private, U.S.-based molecular diagnostics company developing diagnostic assays for adverse pregnancy conditions such as pre-term birth. It employs the proprietary NeXosome® platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation. NX Prenatal is planning the U.S. launch of the  NeXosome Preterm Birth Risk Assay, which detects a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. This technology may provide physicians an ideal opportunity to intervene in a timely manner with protocols for at-risk pregnancies in an attempt to reduce the likelihood of a preterm birth or minimize the complications that can arise for both the child and the mother.

Visit https://www.nxprenatal.com/